Xiaohong Wu

No. 31, Huatuo Road
Beijing, 102629, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Rapid LC-MS Quantification of mRNA Vaccine Capping Efficiency via High-Specificity RNase H Cleavage and Metal Adduct Suppressed Chromatography.

Rapid LC-MS Quantification of mRNA Vaccine Capping Efficiency via High-Specificity RNase H Cleavage and Metal Adduct Suppressed Chromatography.

Journal: Vaccines

Published: May 16, 2026

Immunomodulatory effects of biodegradable Mg-Cu-Zn alloy in esophageal cancer.

Immunomodulatory effects of biodegradable Mg-Cu-Zn alloy in esophageal cancer.

Journal: Bioactive materials

Published: October 23, 2025

Development and validation of a Vero cell DNA standard for residual DNA measurement suitable for quantitative PCR method.

Development and validation of a Vero cell DNA standard for residual DNA measurement suitable for quantitative PCR method.

Journal: Frontiers in microbiology

Published: October 11, 2025

A single ultra-low dose self-amplifying RNA rabies vaccine confers rapid and complete protection in mice.

A single ultra-low dose self-amplifying RNA rabies vaccine confers rapid and complete protection in mice.

Journal: Vaccine

Published: October 09, 2025

A randomized, non-inferiority phase III clinical trial of immunogenicity and safety of 5-dose and 4-dose schedules of a freeze-dried human rabies vaccine (MRC-5 cells) in participants aged 10-60.

A randomized, non-inferiority phase III clinical trial of immunogenicity and safety of 5-dose and 4-dose schedules of a freeze-dried human rabies vaccine (MRC-5 cells) in participants aged 10-60.

Journal: BMC infectious diseases

Published: July 25, 2025

Novel Standard Substance from Primary Hamster Kidney Cells for Quality Control of Human Rabies Vaccines in China.

Novel Standard Substance from Primary Hamster Kidney Cells for Quality Control of Human Rabies Vaccines in China.

Journal: Vaccines

Published: December 24, 2024

Safety and immunogenicity of freeze-dried human rabies vaccines: A phase 3 clinical trial of Zagreb and Essen regimes.

Safety and immunogenicity of freeze-dried human rabies vaccines: A phase 3 clinical trial of Zagreb and Essen regimes.

Journal: Human vaccines & immunotherapeutics

Published: November 13, 2024

Evaluation of the Efficacy of the Vaccine Production Process in Removing Residual Host Cell DNA from the Vero Cell Rabies Vaccine.

Evaluation of the Efficacy of the Vaccine Production Process in Removing Residual Host Cell DNA from the Vero Cell Rabies Vaccine.

Journal: Vaccines

Published: October 25, 2024

Immunogenicity Persistence of Different Immunization Regimens of Rabies Vaccine in the 10-60 Years Age Group: A Follow-Up Report Based on Phase III Clinical Trial.

Immunogenicity Persistence of Different Immunization Regimens of Rabies Vaccine in the 10-60 Years Age Group: A Follow-Up Report Based on Phase III Clinical Trial.

Journal: Vaccines

Published: September 03, 2024

Safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A randomized, blinded controlled phase 3 trial in healthy participants aged 10-60 years old.

Safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A randomized, blinded controlled phase 3 trial in healthy participants aged 10-60 years old.

Journal: Vaccine

Published: July 17, 2024

Corrigendum to "Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic" [Vaccine (2024) 26059].

Corrigendum to "Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic" [Vaccine (2024) 26059].

Journal: Vaccine

Published: July 17, 2024

A SARS-CoV-2 EG.5 mRNA vaccine induces a broad-spectrum immune response in mice.

A SARS-CoV-2 EG.5 mRNA vaccine induces a broad-spectrum immune response in mice.

Journal: MedComm

Published: April 11, 2024

Showing 1-12 of 31

Last Updated: 09/26/2026